Skip to content

Buying a Pharmacy

The Cost of Buying a Pharmacy, and Whether It Is a Good Investment

11 November 2026 · 7 min read

Get in touch

What does it actually cost to buy a pharmacy?

When you buy a whole pharmacy, the price is only one line. On top of it come the transaction tax (which swings with the deal structure), legal and accounting fees, a working-capital buffer for the stock and wages you pay before the first NHS advance lands, and any fit-out the premises need. The return on all that money depends on the NHS contract and dispensing volumes, not the shop or the footfall, so work out the full cost before you start paying advisers.

Whether you can fund it is a separate question, covered in first-time pharmacy buyer finance. So is checking the seller's figures, which pharmacy financial due diligence walks through. Here it's the cost stack, and whether the investment stacks up.

The cost stack, item by item

Here's the calculation with every cost in it, for an illustrative purchase: a £600,000 price, with a £400,000 freehold inside it on the asset-deal line. The price is illustrative because we don't assert a market figure; a pharmacy's price depends on its contract, its volumes and the deal. Every other figure comes from the gov.uk or NHS source named against it, or is left qualitative.

Cost line What drives it Illustrative amount (example only) Source
Purchase price (goodwill-dominated) NHS contract, item volumes, deal structure. Priced on a multiple of adjusted EBITDA and/or a pence-per-item benchmark; the multiple is deal-specific and not asserted here. £600,000 (illustrative) Your heads of terms
Transaction tax (share deal) 0.5% stamp duty on the share consideration, rounded up to the nearest £5 (the Securities Transfer Tax is announced to replace it in late 2027) £3,000 (0.5% of £600,000) gov.uk: Tax when you buy shares
Transaction tax (asset deal, property element) SDLT at non-residential bands on the property only, never on goodwill or the NHS contract: 0% to £150k, 2% £150k to £250k, 5% above £250k. A new lease also pays SDLT on its rent. £9,500 on the £400,000 freehold (breakdown below) gov.uk: SDLT non-residential rates
Professional fees Solicitor (heads of terms, sale agreement, regulatory consents), accounting due diligence, completion accounts. They vary with the deal and the advisers. Qualitative (deal-specific) Your advisers' quotes
Working-capital buffer FP34 declared by the 5th of the month after dispensing; the estimated full-value advance follows around the 10th, the reconciliation about two months after submission. You fund the stock and wages before the first advance. Qualitative (depends on dispensing volumes) NHSBSA: submitting prescriptions; Drug Tariff Part I Clause 5C
Fit-out and equipment Dispensary fit-out, robots, refrigeration, IT and security are plant and machinery. A company buying new main-rate plant normally takes full expensing (100% in the year); any business not on the cash basis can use the Annual Investment Allowance on up to £1,000,000 of qualifying spend, which is the route for second-hand equipment you take over with the business; a sole trader or partnership on the cash basis deducts equipment as an expense instead. Structural works get the Structures and Buildings Allowance at 3% a year. The first-year allowances, and the changes announced at Budget 2026, are on our buying a pharmacy page. Deal-specific; depends on the premises gov.uk: Claim capital allowances

Illustrative total (share deal, £600,000, minimal fit-out): £600,000 plus £3,000 stamp duty, plus fees and the working-capital buffer. The tax line moves with the structure: £6,500 more as an asset deal with the £400,000 freehold in it, or £3,000 less as an asset deal on a leasehold where you take over the existing lease and pay nothing for it (see below). The arithmetic is the point; your own stack depends on the price, structure, premises and advisers.

Business rates aren't a purchase cost, but they come with the keys. In England for 2026/27 the multiplier is 43.2p below £51,000 of rateable value, 48p from £51,000 and 50.8p at £500,000 or more. MHCLG lists chemists among properties eligible for the lower retail, hospitality and leisure multipliers (38.2p and 43p) where they sell directly to the public, but your council decides whether yours qualifies. Small business rate relief takes the bill to nil at a rateable value of £12,000 or less if it's the only property your business uses, tapering up to £15,000.

Run your own numbers through the pharmacy purchase affordability calculator: the monthly repayment, the post-tax cash cover and the stamp duty or SDLT, as a scenario estimate.

Add the purchase price, deposit, loan terms and projected profit to see the monthly repayment, the post-tax cash cover and the stamp duty or SDLT on a share deal against an asset deal.

Calculator

Pharmacy Purchase Affordability Calculator

Enter the purchase price, deposit, loan terms and projected pharmacy profit to see your estimated loan repayments, how well trading cash flow covers the debt, and the acquisition tax cost for a share deal versus an asset deal. Every figure already in the boxes is an example, so replace it with your own; the result on your deal depends on how it's structured.

£

The agreed headline price for the pharmacy. Enter the actual figure from your heads of terms.

£

The amount you are putting in from your own funds. The rest is assumed to be financed by a commercial loan.

The term your lender offers. Shorter terms mean higher repayments but less total interest.

The rate quoted by the lender. The rate you are offered depends on lender, term and loan-to-value.

£

The part of the price that buys land or buildings: a freehold, or what you pay for a lease. Leave at 0 if no property is being bought. SDLT is charged on this figure only, never on goodwill or the NHS contract.

£

Only if you're taking a new lease of the premises. SDLT is due on the rent's net present value at 1% from £150,001 to £5 million and 2% above. HMRC's SDLT calculator works the figure out from the rent and the term.

£

The adjusted EBITDA or trading profit you expect after your salary, before loan interest and tax. The tool takes the first year's interest off before working out corporation tax.

Your result

Your answer's ready. Press below to see it.

The transaction-tax difference: share deal versus asset deal

Shares or assets (the full comparison is in share versus asset purchase) changes the tax bill directly. On the same £600,000:

Share deal

Stamp duty on shares is 0.5% of the consideration once it tops £1,000, rounded up to the nearest £5, so £3,000 here (gov.uk/tax-buy-shares). It's due to be replaced by the Securities Transfer Tax, announced to start in late 2027 by commencement order. You also inherit the company's whole history, undisclosed liabilities included, which is why due diligence on a share deal goes wider.

Asset deal (property element)

SDLT applies at non-residential and mixed-use rates to the property part of the price only, never the goodwill or the NHS contract. The bands match the affordability calculator:

SDLT band Rate Tax on that slice (illustrative, £400,000 freehold)
£0 to £150,000 0% £0
£150,001 to £250,000 2% £2,000
£250,001 to £400,000 5% £7,500
Total SDLT (illustrative) £9,500

A new lease adds SDLT on the rent's net present value: 0% up to £150,000, 1% from £150,001 to £5 million and 2% above. These are the rates for England and Northern Ireland; Wales (Land Transaction Tax) and Scotland (LBTT) have their own.

So with that freehold in the price, the asset deal costs £9,500 against £3,000 on a share deal: £6,500 more. Buy a leasehold pharmacy's assets and take over its existing lease, and SDLT is due only on what you pay for the lease itself, so with nothing paid for it there's no SDLT and the share deal is the dearer one by £3,000. Set the saving against the risk: an asset deal leaves the company's past liabilities with the seller.

Goodwill relief is the other structuring point. A company buying the business gets corporation tax relief on goodwill only at a fixed 6.5% a year, only if qualifying IP assets come with it, and on at most six times the IP's cost. Because goodwill is most of a pharmacy's price, that shapes the real cost; our help splitting the price between goodwill, stock and fixtures covers it.

Want this checked against your specific situation?

Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.

We'll only use your details to respond to your enquiry. We don't pass them to any other firm. See our Privacy Policy.

Is a pharmacy a good investment? The honest case

Both the strengths and the risks are written into the Community Pharmacy Contractual Framework and the Drug Tariff, so neither side is guesswork.

The strengths

Income is contract-backed and recurring. Revenue is reimbursement (Drug Tariff prices for dispensed items) plus remuneration (fees and service payments under the CPCF). It doesn't depend on footfall or marketing, which is why a pharmacy can support acquisition finance in a way a shop living on its takings can't.

Service income is its own revenue line. Pharmacy First and other commissioned services have their own fees, and from 2026/27 the Pharmacy First budget sits inside the contract's £3.636 billion total. See NHS England's Pharmacy First pages and Pharmacy First income accounting.

Demand is steady. Dispensing follows the local population's prescriptions, not discretionary spending. Volumes can still move (a GP practice merges, a patient list shifts), but they don't rise and fall with the economy the way shop sales do.

The risks

Gross margin is set centrally and moves every quarter. Each item is paid at the Drug Tariff price listed for its dispensing month. DHSC resets Category M prices each quarter, and when pharmacies overall have earned above the funded margin, it recoups the excess through lower prices in later quarters (the clawback). For 2026/27 it's writing off up to £239 million of historic net over-delivery and making no price adjustments to recover the rest, but the quarterly resets carry on, and you don't control them. A pharmacy that looked profitable when you bought it can lose margin to a cycle the price didn't allow for. See Category M clawbacks explained and Drug Tariff changes explained.

The payment cycle is a permanent cash-flow lag. You pay the wholesaler and staff as you dispense; NHSBSA's 100% estimated advance arrives around the 10th of the next month and the reconciliation two months after you submit. A late declaration moves the advance back a month or loses it to the reconciliation. The FP34 cash flow estimator shows when one month's money lands against your outgoings.

There's no standard return. It depends on the verified contract income, the volumes, the price and the cost of finance, so no ROI, yield or payback figure applies across deals. Trace any "typical return" a broker or seller quotes back to the FP34-reconciled income, the adjusted EBITDA and the price.

What the return actually depends on

Three things you can verify: the NHS contract and its stability, the item volume (checked against NHSBSA records), and the price you pay against both. The goodwill reflects the contract and the volume, not the premises or the shopfit, so you're paying for the right to dispense NHS prescriptions from that address. That's why the regulatory checks (the NHS Pharmaceutical Regulations 2013 change of ownership, GPhC premises registration) run alongside the financial ones: without the contract and the registered premises, there's no asset.

Shelf sales and private services add to income, but they don't decide the return. Pay for retail upside rather than verified NHS income and you've misread the asset. How goodwill is valued is in pharmacy goodwill: what it is worth; testing the income before exchange is in pharmacy financial due diligence.

Getting a real number for your deal

The figures here show the arithmetic; your real numbers depend on the price, structure, premises, volumes and fees. Two tools model your own case. The pharmacy purchase affordability calculator works out the loan, the monthly repayment, the post-tax cash cover (corporation tax on profit after the first year's loan interest) and the stamp duty or SDLT; it's a scenario estimate, not a lending decision. The FP34 cash flow estimator sizes the buffer you need from day one.

Our pharmacy purchase accounting service covers the work from the first cost model through due diligence, structuring and completion accounts, and the buying a pharmacy hub brings the buying guides, tools and services together.

Frequently asked questions

The total cost is the purchase price (goodwill-dominated, deal-specific) plus transaction tax (0.5% on a share deal, or SDLT on the property element at non-residential rates up to 5% on an asset deal), professional fees for legal and accounting due diligence, a working-capital buffer for the stock and wages paid before the first NHS advance, and any fit-out expenditure. No single market price applies; the purchase affordability calculator works out the repayments, post-tax cash cover and transaction tax for a given scenario.

A pharmacy generates recurring, contract-backed NHS income, which is more predictable than typical retail. The risk is that gross margin is set centrally through the Drug Tariff, and DHSC resets Category M prices each quarter (the clawback works through lower future prices), so the owner does not control the margin. Whether the deal stacks up depends on the verified contract income, dispensing volumes, and the price paid relative to those fundamentals.

The costs that are easy to underestimate are: transaction tax on the deal structure chosen, professional fees for legal and accounting work, a working-capital buffer for the first weeks of ownership, before NHSBSA's first advance lands, and fit-out or equipment spend if the premises need upgrading.

On a share purchase you pay 0.5% stamp duty on the share consideration; the Securities Transfer Tax is announced to replace it in late 2027. On an asset purchase you pay Stamp Duty Land Tax on any property element at non-residential rates: 0% up to £150,000, 2% from £150,001 to £250,000, and 5% above £250,000, and a new lease also pays 1% on the rent's net present value from £150,001 to £5 million and 2% above. That's England and Northern Ireland; Wales and Scotland have their own taxes. Which structure costs more depends on how much property is in the deal.

The return is driven by the NHS contract and dispensing item volumes, which determine reimbursement income and service-fee income. Gross margin is set centrally through the Drug Tariff, with Category M prices reset each quarter, so the buyer cannot improve it by operational effort alone. Service income such as Pharmacy First is a separate element, funded inside the contract's £3.636 billion for 2026/27.

Yes. You declare FP34 prescriptions by the 5th of the month after dispensing, NHSBSA advances the whole estimated claim around the 10th, and the reconciliation comes about two months after you submit. Your first month's stock and wages are paid before that first advance, so the business needs a working-capital buffer from day one of ownership, on top of the purchase price and transaction costs.

Related reading

Need help with your pharmacy finances?

Tell us about your situation and we will come back within 24 hours.

Step 1 of 2 · About you

Optional: a bit more detail (helps us prepare)